

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby
--	---

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual AstraZeneca Pharmaceuticals LP			
2. Address Address1 <u>1800 CONCORD PIKE, P.O. BOX 15437</u> Address2 _____ City <u>WILMINGTON</u> State <u>DE</u> Zip Code <u>19850-5437</u> Country <u>USA</u>			
3. Principal place of business (if different than line 2) City _____ State _____ Zip Code _____ Country _____			
4a. Contact Name Ms. <u>Kate Belinski</u>	b. Telephone Number <u>2026615599</u>	c. E-mail <u>belinskik@ballardspahr.com</u>	5. Senate ID# <u>54073-12</u>
7. Client Name <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality AstraZeneca Pharmaceuticals LP			6. House ID# <u>349750000</u>

TYPE OF REPORT

8. Year 2022 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

<p align="center">12. Lobbying</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input checked="" type="checkbox"/> \$ <u>930,000.00</u></p> <p>14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>
---	---

Signature

Digitally Signed By: Kate Belinski

Date

11/7/2022
10:59:29 AM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 1730/S. 670- Speeding Therapy Access Today Act;
 H.R. 483/S. 350 - Newborn Screening Saves Lives Act;
 H.R. 6000 Cures 2.0 Act;
 H.R. 6584 Diverse and Equitable Participation in Clinical Trials Act;
 S. 2706/H.R. 5030 Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act;
 H.R. 6963 - Accelerated Approval Integrity Act;
 H.R. 6996 – Accelerating Access for Patients Act –
 General issues related to rare disease and orphan drugs;
 General issues related to drug pricing;
 Reauthorization of the FDA User Fee Act;
 FDA modernization policy issues;
 Reauthorization of newborn screening programs;
 Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients;
 General issues related to health equity in rare disease and clinical trials;
 General issues related to diagnostics for patients with rare diseases
 Cancer screening, diagnosis & treatment
 Prescription drug electronic labeling
 H.R. 3 – Elijah E. Cummings Lower Drug Costs Now Act;
 H.R. 19 - Lower Costs, More Cures Act;
 H.R. 5260 - Reduced Costs and Continued Cures Act;
 H.R. 5376 - Build Back Better Act;
 H.R. 7667 - Food and Drug Amendments of 2022;
 S.4348 - FDASLA Act of 2022
 H.R. 7845 - NIH Clinical Trial Diversity Act of 2022;
 H.R 7032 - Increasing Transparency in Generic Drug Applications Act of 2022;
 H.R. 2883, Stop Stalling Access to Affordable Medications
 Issues related to COVID-19 vaccines and therapies;
 Items related to the Administrations Cancer Moonshot
 Prescription Drug User Fee Act (PDUFA)
 H.R. 4128/S. 2209, VALID Act
 S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022
 Pharmaceutical Innovation, generally;

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), White House Office, Office of Science & Technology Policy (OSTP)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New

Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Sarah	Arbes		Asst Secretary for Legislation, Dept of Health and Human Services; Principal Deputy Assistant Secretary for Legislation, Dept of Health and Human Services; Deputy Health Policy Director, U.S. Senate Committee on Health, Education, Labor and Pension	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 3 – Elijah E. Cummings Lower Drug Costs Now Act;
 H.R. 19 - Lower Costs, More Cures Act;
 H.R. 5260 - Reduced Costs and Continued Cures Act;
 H.R. 5376 - The Inflation Reduction Act of 2022;
 General issues related to patient access to rare disease therapies, Part B and Part D drugs; Issues related to home infusion for Part B patients;
 Center for Medicare and Medicaid Innovation (CMMI) policy issues;
 Value-based payment arrangements;
 Efforts to improve coding, coverage, and access for rare disease therapies;
 Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies; General issues related to diagnostic reimbursement
 S. 1873/H.R. 1946 - Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021
 Issues related to preventative services and screenings for underrepresented communities
 H.R 4065/S. 1971 (Section 101) - Expanding Medicare annual wellness benefit to include kidney disease screening
 CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure
 General issues related to diagnostic reimbursement

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes		Asst Secretary for Legislation, Dept of Health and Human Services; Principal Deputy Assistant Secretary for Legislation, Dept of Health and Human Services; Deputy Health Policy Director, U.S. Senate Committee on Health, Education, Labor and Pension	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

H.R. 7559 and issues related to an appropriations hold on funding for a 2014 FDA rule that would provide electronic flexibilities related to package inserts
 Issues related to the 340B drug discount program

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes		Asst Secretary for Legislation, Dept of Health and Human Services; Principal Deputy Assistant Secretary for Legislation, Dept of Health and Human Services; Deputy Health Policy Director, U.S. Senate Committee on Health, Education, Labor and Pension	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act
 H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
 H.R. 2883, Stop Stalling Access to Affordable Medications
 H.R. 2891 Preserve Access to Affordable Generics and Biosimilars Act
 H.R. 4521, H. Rept. 117-235 America COMPETES Act of 2022
 H.R. 7032, Increasing Transparency in Generic Drug Applications Act of 2022
 S. 1435, the Affordable Prescriptions for Patients Act
 S. 1425, Stop STALLING Act
 Issues related to the World Trade Organization (WTO) waiver on Trade-related Aspects of Intellectual Property Rights (TRIPS) for COVID-19 vaccines

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Aaron	Hunter			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Sarah	Arbes		Asst Secretary for Legislation, Dept of Health and Human Services; Principal Deputy Assistant Secretary for Legislation, Dept of Health and Human Services; Deputy Health Policy Director, U.S. Senate Committee on Health, Education, Labor and Pension	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

H.R. 2623 – Cameron’s Law
 H.R. 5376 - Build Back Better Act
 Issues related to the Orphan Drug Tax Credit
 Issues related to the deduction of research and development expenditures
 Issues related to corporate and international tax reform
 S. 749/H.R 1304 - American Innovation and Jobs Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Sarah	Arbes		Asst Secretary for Legislation, Dept of Health and Human Services; Principal Deputy Assistant Secretary for Legislation, Dept of Health and Human Services; Deputy Health Policy Director, U.S. Senate Committee on Health, Education, Labor and Pension	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Appropriations, FY 2023;
 H.R. 8239, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
 H.R. 6833, P.L. 117-180, Affordable Insulin Now Act
 H.R. 8294, transportation, Housing and Urban Development, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2023
 H.R. 8295/S. 4659, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Sarah	Arbes		Asst Secretary for Legislation, Dept of Health and Human Services; Principal Deputy Assistant Secretary for Legislation, Dept of Health and Human Services; Deputy Health Policy Director, U.S. Senate Committee on Health, Education, Labor and Pension	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform
 S. 4417, the PTAB Reform Act
 TRIPS IP Waiver
 Issues related to manufacturer patent protections at the World Health Organization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Sarah	Arbes		Asst Secretary for Legislation, Dept of Health and Human Services; Principal Deputy Assistant Secretary for Legislation, Dept of Health and Human Services; Deputy Health Policy Director, U.S. Senate Committee on Health, Education, Labor and Pension	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENV

16. Specific lobbying issues

Sustainability & Zero Carbon; Items related to environmental sustainability and our Ambition Zero Carbon efforts

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Sarah	Arbes		Asst Secretary for Legislation, Dept of Health and Human Services; Principal Deputy Assistant Secretary for Legislation, Dept of Health and Human Services; Deputy Health Policy Director, U.S. Senate Committee on Health, Education, Labor and Pension	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOR

16. Specific lobbying issues

Amendment to Montreal Protocol ("Kigali Amendment")

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Caroline	Quat			<input type="checkbox"/>
Sarah	Arbes		Asst Secretary for Legislation, Dept of Health and Human Services; Principal Deputy Assistant Secretary for Legislation, Dept of Health and Human Services; Deputy Health Policy Director, U.S. Senate Committee on Health, Education, Labor and Pension	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address _____
 City _____ State _____ Zip Code _____ Country _____

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ Country _____

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
------------	-----------	--------	------------	-----------	--------

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)	
	Street Address City	State/Province	Zip	Country	City State	Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address City	State/Province	Country			

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No Yes

Lobbyist Name	Description of Offense(s)
---------------	---------------------------